查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美的藥物輔助性治療(MAT)市場 - 產業趨勢和至2029年的預測
市場調查報告書
商品編碼
1100103

北美的藥物輔助性治療(MAT)市場 - 產業趨勢和至2029年的預測

NA Medication Assisted (MAT) Treatment Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 232 Pages | 商品交期: 請詢問到貨日

價格

北美的藥物輔助性治療(MAT)的市場規模，預計2022年～2029年的預測期間以9.7％的年複合成長率擴大。

本報告提供北美的藥物輔助性治療(MAT)的相關調查，市場概要，以及各類型，各產品，各藥物類型，各劑型，各給藥途徑，各人口類型，各終端用戶，各流通管道，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 北美的藥物輔助性治療(MAT)市場:市場區隔

第3章 摘要整理

第4章 重要考察

第5章 北美的藥物輔助性治療(MAT)市場:法規

第6章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第7章 北美的藥物輔助性治療(MAT)市場，各類型

  • 概要
  • 投藥
  • 治療

第8章 北美的藥物輔助性治療(MAT)市場，各產品

  • 概要
  • BUPRENORPHINE與NALOXONE
  • NALTREXONE
  • BUPRENORPHINE
  • METHADONE
  • NALOXONE
  • DISULFIRAM
  • ACAMPROSATE

第9章 北美的藥物輔助性治療(MAT)市場，各藥物類型

  • 概要
  • 非專利
  • 品牌

第10章 北美的藥物輔助性治療(MAT)市場，各劑型

  • 概要
  • 速放劑
  • 徐放劑

第11章 北美的藥物輔助性治療(MAT)市場，各給藥途徑

  • 概要
  • 口服
  • 非口服
  • 其他

第12章 北美的藥物輔助性治療(MAT)市場，各人口類型

  • 概要
  • 大人
  • 10代

第13章 北美的藥物輔助性治療(MAT)市場，各終端用戶

  • 概要
  • 復建診所
  • 醫院
  • 專門中心
  • 居家護理
  • 其他

第14章 北美的藥物輔助性治療(MAT)市場，各流通管道

  • 概要
  • 院內藥局
  • 直接競標
  • 零售藥局
  • 線上藥局
  • 其他

第15章 北美的藥物輔助性治療(MAT)市場，各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥

第16章 北美的藥物輔助性治療(MAT)市場:企業形勢

  • 企業佔有率分析:北美

第17章 SWOT分析

第18章 企業簡介

  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • INDIVOR PLC
  • VIATRIS INC
  • SUN PHARMACEUTICAL INDUSTRIES LTD
  • ALKERMES
  • PURDUE PHARMA L.P.
  • PFIZER
  • GLENMARK PHARMACEUTICAL INC
  • DR. REDDY'S LABORATORIES LTD
  • ALVOGEN
  • ADAMIS PHARMACEUTICALS CORPORATION
  • ACCORD HEALTHCARE
  • AMNEAL PHARMACEUTICALS LLC
  • AMERICAN ADDICTION CENTERS
  • HIKMA PHARMACEUTICALS PLC
  • LANNETT
  • MALLINCKRODT
  • OREXO US INC
  • PINNACLE TREATMENT CENTERS
  • RECOVERY CENTERS OF AMERICA
  • TAJ PHARMACEUTICALS LIMITED
  • TITAN PHARMACEUTICALS
  • VISTAPHARM, INC

第19章 問卷調查

第20章 相關報告

The North America medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 9.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

North America Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of North America medication-assisted treatment (MAT) are:

The rise in the population receiving medication-assisted treatment (MAT)

Availability of reimbursement for medication-assisted treatment (MAT)

Market Players:

Some of the major players operating in the North America medication-assisted treatment (MAT) market are:

Indivior PLC

Orexo US Inc (a subsidiary of Orexo AB)

Recovery Centers of America

Alkermes

Sun Pharmaceutical Industries Ltd.

Purdue Pharma L.P.

Taj Pharmaceuticals Limited

Lannett

Hikma Pharmaceuticals PLC

Pfizer Inc.

Pinnacle Treatment Center

American Addiction Centers

Adamis Pharmaceuticals Corporation

Glenmark Pharmaceutical Inc.

Viatris Inc.

Mallinckrodt

Alvogen

VistaPharm, Inc.

Teva Pharmaceutical Industries Ltd.

Dr. Reddy's Laboratories Ltd.

Amneal Pharmaceuticals LLC.

Titan Pharmaceuticals, Inc.

TABLE OF CONTENTS

1 INTRODUCTION 49

  • 1.1 OBJECTIVES OF THE STUDY 49
  • 1.2 MARKET DEFINITION 49
  • 1.3 OVERVIEW OF NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET 49
  • 1.4 CURRENCY AND PRICING 52
  • 1.5 LIMITATIONS 52
  • 1.6 MARKETS COVERED 53

2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 57

  • 2.1 MARKETS COVERED 57
  • 2.2 GEOGRAPHICAL SCOPE 58
  • 2.3 YEARS CONSIDERED FOR THE STUDY 59
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 60
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
  • 2.6 MULTIVARIATE MODELLING 64
  • 2.7 PRODUCT SEGMENT LIFELINE CURVE 64
  • 2.8 DBMR MARKET POSITION GRID 65
  • 2.9 VENDOR SHARE ANALYSIS 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 SECONDARY SOURCES 69

3 EXECUTIVE SUMMARY 70

4 PREMIUM INSIGHTS 74

  • 4.1 EPIDEMIOLOGY 75
  • 4.2 PESTEL 76
  • 4.3 PORTER'S FIVE FORCES MODEL 77
  • 4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021) 78
  • 4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021) 78
  • 4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021) 79
  • 4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021) 79
  • 4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET 80

5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS 81

6 MARKET OVERVIEW 84

  • 6.1 DRIVERS 86
    • 6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS 86
    • 6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 87
    • 6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT) 87
    • 6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 88
  • 6.2 RESTRAINTS 89
    • 6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT) 89
    • 6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT) 89
    • 6.2.3 RISE IN PRODUCT RECALLS 89
  • 6.3 OPPORTUNITIES 90
    • 6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 90
    • 6.3.2 RISE IN HEALTHCARE EXPENDITURE 91
  • 6.4 CHALLENGES 91
    • 6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT 91
    • 6.4.2 STRINGENT REGULATIONS 92
    • 6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT) 93

7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE 94

  • 7.1 OVERVIEW 95
  • 7.2 MEDICATION 98
    • 7.2.1 OPIOID DEPENDENCY MEDICATION 99
      • 7.2.1.1 BUPRENORPHINE AND NALOXONE 99
      • 7.2.1.2 BUPRENORPHINE 99
      • 7.2.1.3 METHADONE 99
      • 7.2.1.4 NALTREXONE 100
    • 7.2.2 ALCOHOL USE DISORDER MEDICATIONS 100
      • 7.2.2.1 NALTREXONE 100
      • 7.2.2.2 DISULFIRAM 100
      • 7.2.2.3 ACAMPROSATE 100
    • 7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION 100
      • 7.2.3.1 NALOXONE 101

 

  • 7.3 THERAPY 101
    • 7.3.1 BEHAVIORAL THERAPY 102
    • 7.3.2 EDUCATIONAL THERAPY 102
    • 7.3.3 COUNSELLING 102
    • 7.3.4 VOCATIONAL THERAPY 102
    • 7.3.5 OTHERS 103

8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS 104

  • 8.1 OVERVIEW 105
  • 8.2 BUPRENORPHINE AND NALOXONE 108
  • 8.3 NALTREXONE 108
  • 8.4 BUPRENORPHINE 110
  • 8.5 METHADONE 110
  • 8.6 NALOXONE 111
  • 8.7 DISULFIRAM 112
  • 8.8 ACAMPROSATE 113

9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE 114

  • 9.1 OVERVIEW 115
  • 9.2 GENERICS 118
  • 9.3 BRANDED 118
    • 9.3.1 SUBOXONE 119
    • 9.3.2 VIVITROL 119
    • 9.3.3 BUTRANS 119
    • 9.3.4 ZUBSOLV 120
    • 9.3.5 PROBUPHINE 120
    • 9.3.6 OTHERS 120

10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM 121

  • 10.1 OVERVIEW 122
  • 10.2 IMMEDIATE RELEASE 125
  • 10.3 EXTENDED RELEASE 125

 

11 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION 127

  • 11.1 OVERVIEW 128
  • 11.2 ORAL 131
    • 11.2.1 TABLET 132
    • 11.2.2 SUBLINGUAL FILM 132
    • 11.2.3 OTHERS 132
  • 11.3 PARENTERAL 132
    • 11.3.1 SOLUTION 133
    • 11.3.2 SUSPENSION 133
  • 11.4 OTHERS 134

12 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE 135

  • 12.1 OVERVIEW 136
  • 12.2 ADULTS 139
  • 12.3 TEENAGE 139

13 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER 141

  • 13.1 OVERVIEW 142
  • 13.2 REHABILITATION CLINICS 145
  • 13.3 HOSPITALS 145
  • 13.4 SPECIALTY CENTERS 146
  • 13.5 HOMECARE 147
  • 13.6 OTHERS 148

14 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL 149

  • 14.1 OVERVIEW 150
  • 14.2 HOSPITAL PHARMACY 153
  • 14.3 DIRECT TENDER 153
  • 14.4 RETAIL PHARMACY 154
  • 14.5 ONLINE PHARMACY 155
  • 14.6 OTHERS 156

 

15 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION 157

  • 15.1 NORTH AMERICA 158
    • 15.1.1 U.S. 168
    • 15.1.2 CANADA 173
    • 15.1.3 MEXICO 178

16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE 183

  • 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 183

17 SWOT ANALYSIS 184

18 COMPANY PROFILE 185

  • 18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021) 185
    • 18.1.1 COMPANY SNAPSHOT 185
    • 18.1.2 REVENUE ANALYSIS 186
    • 18.1.3 COMPANY SHARE ANALYSIS 186
    • 18.1.4 PRODUCT PORTFOLIO 186
    • 18.1.5 RECENT DEVELOPMENTS 187
  • 18.2 INDIVOR PLC (2021) 188
    • 18.2.1 COMPANY SNAPSHOT 188
    • 18.2.2 REVENUE ANALYSIS 188
    • 18.2.3 COMPANY SHARE ANALYSIS 189
    • 18.2.4 PRODUCT PORTFOLIO 189
    • 18.2.5 RECENT DEVELOPMENTS 190
  • 18.3 VIATRIS INC (2021) 191
    • 18.3.1 COMPANY SNAPSHOT 191
    • 18.3.2 REVENUE ANALYSIS 191
    • 18.3.3 COMPANY SHARE ANALYSIS 192
    • 18.3.4 PRODUCT PORTFOLIO 192
    • 18.3.5 RECENT DEVELOPMENTS 192
  • 18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021) 193
    • 18.4.1 COMPANY SNAPSHOT 193
    • 18.4.2 REVENUE ANALYSIS 193
    • 18.4.3 COMPANY SHARE ANALYSIS 194
    • 18.4.4 PRODUCT PORTFOLIO 194
    • 18.4.5 RECENT DEVELOPMENTS 194

 

  • 18.5 ALKERMES (2021) 195
    • 18.5.1 COMPANY SNAPSHOT 195
    • 18.5.2 REVENUE ANALYSIS 195
    • 18.5.3 COMPANY SHARE ANALYSIS 196
    • 18.5.4 PRODUCT PORTFOLIO 196
    • 18.5.5 RECENT DEVELOPMENTS 197
  • 18.6 PURDUE PHARMA L.P. (2021) 198
    • 18.6.1 COMPANY SNAPSHOT 198
    • 18.6.2 PRODUCT PORTFOLIO 198
    • 18.6.3 RECENT DEVELOPMENTS 198
  • 18.7 PFIZER (2021) 199
    • 18.7.1 COMPANY SNAPSHOT 199
    • 18.7.2 REVENUE ANALYSIS 199
    • 18.7.3 PRODUCT PORTFOLIO 200
    • 18.7.4 RECENT DEVELOPMENTS 200
  • 18.8 GLENMARK PHARMACEUTICAL INC (2021) 201
    • 18.8.1 COMPANY SNAPSHOT 201
    • 18.8.2 REVENUE ANALYSIS 201
    • 18.8.3 PRODUCT PORTFOLIO 202
    • 18.8.4 RECENT DEVELOPMENTS 202
  • 18.9 DR. REDDY'S LABORATORIES LTD (2021) 203
    • 18.9.1 COMPANY SNAPSHOT 203
    • 18.9.2 REVENUE ANALYSIS 203
    • 18.9.3 PRODUCT PORTFOLIO 204
    • 18.9.4 RECENT DEVELOPMENTS 204
  • 18.10 ALVOGEN (2021) 205
    • 18.10.1 COMPANY SNAPSHOT 205
    • 18.10.2 PRODUCT PORTFOLIO 205
    • 18.10.3 RECENT DEVELOPMENTS 205
  • 18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021) 206
    • 18.11.1 COMPANY SNAPSHOT 206
    • 18.11.2 REVENUE ANALYSIS 206
    • 18.11.3 PRODUCT PORTFOLIO 207
    • 18.11.4 RECENT DEVELOPMENTS 207
  • 18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS) 208
    • 18.12.1 COMPANY SNAPSHOT 208
    • 18.12.2 PRODUCT PORTFOLIO 208
    • 18.12.3 RECENT DEVELOPMENTS 209

 

  • 18.13 AMNEAL PHARMACEUTICALS LLC (2021) 210
    • 18.13.1 COMPANY SNAPSHOT 210
    • 18.13.2 REVENUE ANALYSIS 210
    • 18.13.3 PRODUCT PORTFOLIO 211
    • 18.13.4 RECENT DEVELOPMENTS 211
  • 18.14 AMERICAN ADDICTION CENTERS (2021) 212
    • 18.14.1 COMPANY SNAPSHOT 212
    • 18.14.2 PRODUCT PORTFOLIO 212
    • 18.14.3 RECENT DEVELOPMENTS 212
  • 18.15 HIKMA PHARMACEUTICALS PLC (2021) 213
    • 18.15.1 COMPANY SNAPSHOT 213
    • 18.15.2 REVENUE ANALYSIS 213
    • 18.15.3 PRODUCT PORTFOLIO 214
    • 18.15.4 RECENT DEVELOPMENTS 214
  • 18.16 LANNETT (2021) 215
    • 18.16.1 COMPANY SNAPSHOT 215
    • 18.16.2 REVENUE ANALYSIS 215
    • 18.16.3 PRODUCT PORTFOLIO 216
    • 18.16.4 RECENT DEVELOPMENT 216
  • 18.17 MALLINCKRODT (2021) 217
    • 18.17.1 COMPANY SNAPSHOT 217
    • 18.17.2 REVENUE ANALYSIS 217
    • 18.17.3 PRODUCT PORTFOLIO 218
    • 18.17.4 RECENT DEVELOPMENT 218
  • 18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021) 219
    • 18.18.1 COMPANY SNAPSHOT 219
    • 18.18.2 REVENUE ANALYSIS 219
    • 18.18.3 PRODUCT PORTFOLIO 220
    • 18.18.4 RECENT DEVELOPMENT 220
  • 18.19 PINNACLE TREATMENT CENTERS 221
    • 18.19.1 COMPANY SNAPSHOT 221
    • 18.19.2 PRODUCT PORTFOLIO 221
    • 18.19.3 RECENT DEVELOPMENT 221
  • 18.20 RECOVERY CENTERS OF AMERICA 222
    • 18.20.1 COMPANY SNAPSHOT 222
    • 18.20.2 PRODUCT PORTFOLIO 222
    • 18.20.3 RECENT DEVELOPMENTS 223

 

  • 18.21 TAJ PHARMACEUTICALS LIMITED 224
    • 18.21.1 COMPANY SNAPSHOT 224
    • 18.21.2 PRODUCT PORTFOLIO 224
    • 18.21.3 RECENT DEVELOPMENTS 224
  • 18.22 TITAN PHARMACEUTICALS (2021) 225
    • 18.22.1 COMPANY SNAPSHOT 225
    • 18.22.2 REVENUE ANALYSIS 225
    • 18.22.3 PRODUCT PORTFOLIO 226
    • 18.22.4 RECENT DEVELOPMENTS 226
  • 18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021)) 227
    • 18.23.1 COMPANY SNAPSHOT 227
    • 18.23.2 PRODUCT PORTFOLIO 227
    • 18.23.3 RECENT DEVELOPMENTS 227

19 QUESTIONNAIRE 228

20 RELATED REPORTS 232

LIST OF TABLES

  • TABLE 1 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 68
  • TABLE 2 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 69
  • TABLE 3 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 70
  • TABLE 4 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 70
  • TABLE 5 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 71
  • TABLE 6 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 72
  • TABLE 7 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 73
  • TABLE 8 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 73
  • TABLE 9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 78
  • TABLE 10 NORTH AMERICA BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 79
  • TABLE 11 NORTH AMERICA NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 80
  • TABLE 12 NORTH AMERICA BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 13 NORTH AMERICA METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 82
  • TABLE 14 NORTH AMERICA NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 83
  • TABLE 15 NORTH AMERICA DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 84
  • TABLE 16 NORTH AMERICA ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 84
  • TABLE 17 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 88
  • TABLE 18 NORTH AMERICA GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 19 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 20 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 90
  • TABLE 21 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 95
  • TABLE 22 NORTH AMERICA IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 96
  • TABLE 23 NORTH AMERICA EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 97
  • TABLE 24 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 101
  • TABLE 25 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 102
  • TABLE 26 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 103
  • TABLE 27 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 104
  • TABLE 28 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 104
  • TABLE 29 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 105
  • TABLE 30 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 109
  • TABLE 31 NORTH AMERICA ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 32 NORTH AMERICA TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 111
  • TABLE 33 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 115
  • TABLE 34 NORTH AMERICA REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 116
  • TABLE 35 NORTH AMERICA HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 117
  • TABLE 36 NORTH AMERICA SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 118
  • TABLE 37 NORTH AMERICA HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 118
  • TABLE 38 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 119
  • TABLE 39 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 123
  • TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 124
  • TABLE 41 NORTH AMERICA DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 125
  • TABLE 42 NORTH AMERICA RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 126
  • TABLE 43 NORTH AMERICA ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 126
  • TABLE 44 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 127
  • TABLE 45 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 134
  • TABLE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 47 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 48 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 49 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 50 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 51 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 52 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 136
  • TABLE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 54 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 55 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 137
  • TABLE 56 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 137
  • TABLE 57 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 137
  • TABLE 58 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 137
  • TABLE 59 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 60 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 138
  • TABLE 61 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 138
  • TABLE 62 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 63 U.S. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 64 U.S. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 65 U.S. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 66 U.S. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 67 U.S. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 68 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 140
  • TABLE 69 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 70 U.S. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 71 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 141
  • TABLE 72 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 141
  • TABLE 73 U.S. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 142
  • TABLE 74 U.S. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 142
  • TABLE 75 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 76 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 142
  • TABLE 77 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 143
  • TABLE 78 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 79 CANADA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 80 CANADA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 81 CANADA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 82 CANADA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 83 CANADA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 84 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 145
  • TABLE 85 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 86 CANADA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 87 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 146
  • TABLE 88 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 146
  • TABLE 89 CANADA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 147
  • TABLE 90 CANADA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 147
  • TABLE 91 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 147
  • TABLE 92 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 147
  • TABLE 93 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 148
  • TABLE 94 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 95 MEXICO MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 96 MEXICO OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 97 MEXICO ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 98 MEXICO OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 99 MEXICO THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 100 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 151
  • TABLE 101 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 102 MEXICO BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 103 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 152
  • TABLE 104 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 152
  • TABLE 105 MEXICO ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 152
  • TABLE 106 MEXICO PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 152
  • TABLE 107 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 153
  • TABLE 108 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 153
  • TABLE 109 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 153

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION 27
  • FIGURE 2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION 30
  • FIGURE 3 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS 31
  • FIGURE 4 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 32
  • FIGURE 5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS 32
  • FIGURE 6 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS 33
  • FIGURE 7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID 35
  • FIGURE 8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS 37
  • FIGURE 9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID 38
  • FIGURE 10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 42
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 43
  • FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029 44
  • FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029 44
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET 55
  • FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019 56
  • FIGURE 16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021 65
  • FIGURE 17 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION) 66
  • FIGURE 18 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029) 66
  • FIGURE 19 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE 67
  • FIGURE 20 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021 75
  • FIGURE 21 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION) 75
  • FIGURE 22 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029) 76
  • FIGURE 23 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE 77
  • FIGURE 24 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021 85
  • FIGURE 25 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 86
  • FIGURE 26 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029) 86
  • FIGURE 27 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE 87
  • FIGURE 28 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021 92
  • FIGURE 29 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION) 93
  • FIGURE 30 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029) 93
  • FIGURE 31 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE 94
  • FIGURE 32 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021 98
  • FIGURE 33 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 99
  • FIGURE 34 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 99
  • FIGURE 35 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 100
  • FIGURE 36 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021 106
  • FIGURE 37 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION) 107
  • FIGURE 38 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029) 107
  • FIGURE 39 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE 108
  • FIGURE 40 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021 112
  • FIGURE 41 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION) 113
  • FIGURE 42 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029) 113
  • FIGURE 43 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE 114
  • FIGURE 44 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021 120
  • FIGURE 45 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 121
  • FIGURE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 121
  • FIGURE 47 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 122
  • FIGURE 48 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021) 129
  • FIGURE 49 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021) 131
  • FIGURE 50 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029) 131
  • FIGURE 51 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029) 132
  • FIGURE 52 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029) 132
  • FIGURE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%) 153